Wie kann man die Effektivität multimodaler Therapiekonzepte evaluieren? Aus der Sicht des Pathologen.

K. Becker; U. Fink; K. Ott; R. Busch; J. R. Siewert; H. Höfler

Wie kann man die Effektivität multimodaler Therapiekonzepte evaluieren? Aus der Sicht des Pathologen.

Translated title of the contribution: How can the effectiveness of multimodality therapy concepts be evaluated? From the viewpoint of the pathologist

K. Becker, U. Fink, K. Ott, R. Busch, J. R. Siewert, H. Höfler

TUM Emeriti of Excellence

Technical University of Munich

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Prognostically relevant histopathological grading of tumor regression (grades I-III) is possible, although laborious. Morphological changes after chemotherapy indicate a specific response to treatment with central fibrosis and residual tumor islands in the periphery. Prognostic factors, such as TNM categories, UICC-R status, tumor size, and lymphangiosis, which are not intrinsic part of regression grading still correlate with patient survival.

Translated title of the contribution	How can the effectiveness of multimodality therapy concepts be evaluated? From the viewpoint of the pathologist
Original language	German
Pages (from-to)	58-62
Number of pages	5
Journal	Kongressband / Deutsche Gesellschaft für Chirurgie. Deutsche Gesellschaft für Chirurgie. Kongress
Volume	118
State	Published - 2001

Cite this

@article{72c8f098f7d840928b80d56a43c03538,

title = "Wie kann man die Effektivit{\"a}t multimodaler Therapiekonzepte evaluieren? Aus der Sicht des Pathologen.",

abstract = "Prognostically relevant histopathological grading of tumor regression (grades I-III) is possible, although laborious. Morphological changes after chemotherapy indicate a specific response to treatment with central fibrosis and residual tumor islands in the periphery. Prognostic factors, such as TNM categories, UICC-R status, tumor size, and lymphangiosis, which are not intrinsic part of regression grading still correlate with patient survival.",

author = "K. Becker and U. Fink and K. Ott and R. Busch and Siewert, {J. R.} and H. H{\"o}fler",

year = "2001",

language = "Deutsch",

volume = "118",

pages = "58--62",

journal = "Kongressband / Deutsche Gesellschaft f{\"u}r Chirurgie. Deutsche Gesellschaft f{\"u}r Chirurgie. Kongress",

publisher = "Springer Verlag",

}

TY - JOUR

T1 - Wie kann man die Effektivität multimodaler Therapiekonzepte evaluieren? Aus der Sicht des Pathologen.

AU - Becker, K.

AU - Fink, U.

AU - Ott, K.

AU - Busch, R.

AU - Siewert, J. R.

AU - Höfler, H.

PY - 2001

Y1 - 2001

N2 - Prognostically relevant histopathological grading of tumor regression (grades I-III) is possible, although laborious. Morphological changes after chemotherapy indicate a specific response to treatment with central fibrosis and residual tumor islands in the periphery. Prognostic factors, such as TNM categories, UICC-R status, tumor size, and lymphangiosis, which are not intrinsic part of regression grading still correlate with patient survival.

AB - Prognostically relevant histopathological grading of tumor regression (grades I-III) is possible, although laborious. Morphological changes after chemotherapy indicate a specific response to treatment with central fibrosis and residual tumor islands in the periphery. Prognostic factors, such as TNM categories, UICC-R status, tumor size, and lymphangiosis, which are not intrinsic part of regression grading still correlate with patient survival.

UR - http://www.scopus.com/inward/record.url?scp=0035756225&partnerID=8YFLogxK

M3 - Artikel

C2 - 11824319

AN - SCOPUS:0035756225

VL - 118

SP - 58

EP - 62

JO - Kongressband / Deutsche Gesellschaft für Chirurgie. Deutsche Gesellschaft für Chirurgie. Kongress

JF - Kongressband / Deutsche Gesellschaft für Chirurgie. Deutsche Gesellschaft für Chirurgie. Kongress

ER -

Wie kann man die Effektivität multimodaler Therapiekonzepte evaluieren? Aus der Sicht des Pathologen.

Abstract

Other files and links

Fingerprint

Cite this